CGH
MNTA

Crossmark Global Holdings’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Crossmark Global Holdings’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,700
Closed -$562K – 1458
2020
Q3 		$562K Buy
10,700
+60
+0.6% +$2.48K 0.02% 723
2020
Q2 		$354K Buy
10,640
+820
+8% +$26.1K 0.01% 920
2020
Q1 		$267K Buy
+9,820
New +$273K 0.01% 918
2018
Q4 		– Sell
-23,453
Closed -$617K – 1602
2018
Q3 		$617K Sell
23,453
-320
-1% -$8.65K 0.02% 823
2018
Q2 		$486K Buy
23,773
+1,560
+7% +$33.5K 0.01% 966
2018
Q1 		$403K Sell
22,213
-1,833
-8% -$30.6K 0.01% 1069
2017
Q4 		$335K Buy
24,046
+6,813
+40% +$92.1K 0.01% 1304
2017
Q3 		$319K Buy
+17,233
New +$288K 0.01% 1274
2016
Q3 		$319K Buy
+17,233
New +$203K 0.01% 1274

Crossmark Global Holdings's MNTA Position: Q4 2020 in Review

Crossmark Global Holdings sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 10,700 shares — an estimated $562K sold.

Crossmark Global Holdings first reported a position in MNTA in Q3 2016 and held it in 9 quarters. The position peaked at $617K in Q3 2018. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.

  • Crossmark Global Holdings reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Crossmark Global Holdings sold 10,700 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $562K.
  • Crossmark Global Holdings first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2016 and held it in 9 quarters.
  • Crossmark Global Holdings's Momenta Pharmaceuticals, Inc. position peaked at $617K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.

Based on Crossmark Global Holdings's 13F filing for Q4 2020, filed 14 Jan 2021.